Assessment of Days Alive Out of Hospital as a Possible End Point in Trials of Stroke Prevention for Atrial Fibrillation: A ROCKET AF Analysis.
Josephine HarringtonAnne S HellkampKenneth W MahaffeyGuenter BreithardtJonathan L HalperinGraeme J HankeyRichard C BeckerChristopher C NesselScott D BerkowitzKeith A A FoxDaniel E SingerShaun G GoodmanManesh R PatelJonathan P PicciniPublished in: Journal of the American Heart Association (2024)
DAOH did not identify a treatment difference between patients randomized to rivaroxaban versus warfarin. This may be driven in part by the low overall event rates in atrial fibrillation anticoagulation trials, which leads to substantial left skew in measures of DAOH.
Keyphrases
- atrial fibrillation
- oral anticoagulants
- left atrial
- catheter ablation
- direct oral anticoagulants
- left atrial appendage
- heart failure
- end stage renal disease
- ejection fraction
- newly diagnosed
- percutaneous coronary intervention
- open label
- healthcare
- double blind
- prognostic factors
- clinical trial
- emergency department
- placebo controlled
- patient reported outcomes
- blood brain barrier
- replacement therapy
- left ventricular
- adverse drug
- subarachnoid hemorrhage
- smoking cessation
- study protocol